Pola-R-CHP is a frontline chemotherapy regimen used for diffuse large B-cell lymphoma (DLBCL), especially high-risk or aggressive subtypes. It substitutes polatuzumab vedotin for vincristine in the traditional R-CHOP regimen.
Pola-R-CHP Components:
| Drug | Role / Mechanism |
|---|---|
| Pola – Polatuzumab vedotin | Anti-CD79b antibody–drug conjugate; delivers MMAE (microtubule inhibitor) |
| R – Rituximab | Anti-CD20 monoclonal antibody |
| C – Cyclophosphamide | Alkylating agent |
| H – Doxorubicin (Hydroxydaunorubicin) | Anthracycline; topoisomerase II inhibitor |
| P – Prednisone | Corticosteroid; lympholytic |
Typical Dosing (21-day cycles):
- Polatuzumab vedotin: 1.8 mg/kg IV on Day 1
- Rituximab: 375 mg/m² IV on Day 1
- Cyclophosphamide: 750 mg/m² IV on Day 1
- Doxorubicin: 50 mg/m² IV on Day 1
- Prednisone: 100 mg PO daily on Days 1–5
Vincristine is omitted in this regimen.
Indication:
- Untreated DLBCL (especially ABC subtype or high-risk patients)
- Alternative to R-CHOP, based on POLARIX trial data showing progression-free survival benefit
Key Toxicities:
- Myelosuppression (neutropenia, anemia)
- Peripheral neuropathy (from MMAE in polatuzumab)
- Infusion reactions (especially with rituximab and polatuzumab)
- GI toxicity (nausea, diarrhea)
- Fatigue, infections
Pharmacist Considerations:
- Monitor for neuropathy (Pola-related)
- Premedications for rituximab and polatuzumab (antihistamine, antipyretic)
- Growth factor support (G-CSF) may be considered
- No vincristine → reduced neurotoxicity vs. R-CHOP
- Ensure MMAE-specific precautions (e.g., handling as cytotoxic)